Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.

Teladoc Health posts a y/y narrower Q1 loss and beats revenue estimates as international growth and cost cuts offset BetterHelp weakness and subscription declines.

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

Teladoc Health Inc (NYSE:TDOC) shares are tumbling during Thursday's pre-market session after the company posted mixed quarterly results and issued guidance that points to continued losses. Here's what investors need to know.

Teladoc Health, Inc. (TDOC) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teladoc (TDOC) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.19 per share a year ago.

Teladoc Health (NYSE:TDOC) reported mixed first-quarter financial results that have shares falling on Wednesday after market close.

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 (“First Quarter 2026”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2025 (“First Quarter 2025”).

HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.